[go: up one dir, main page]

NO20066070L - Fremgangsmate for formulering av hurtig-dispergerende former omfattende minst et fiske gelatin valgt pa grunnlag av molekylvekt - Google Patents

Fremgangsmate for formulering av hurtig-dispergerende former omfattende minst et fiske gelatin valgt pa grunnlag av molekylvekt

Info

Publication number
NO20066070L
NO20066070L NO20066070A NO20066070A NO20066070L NO 20066070 L NO20066070 L NO 20066070L NO 20066070 A NO20066070 A NO 20066070A NO 20066070 A NO20066070 A NO 20066070A NO 20066070 L NO20066070 L NO 20066070L
Authority
NO
Norway
Prior art keywords
molecular weight
gelatin
carrier
basis
fish gelatin
Prior art date
Application number
NO20066070A
Other languages
English (en)
Other versions
NO342135B1 (no
Inventor
Andrzej Jan Brzozowski
Leon Paul Grother
Desmond Yik Teng Wong
Original Assignee
Scherer Technologies Inc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Inc R P filed Critical Scherer Technologies Inc R P
Publication of NO20066070L publication Critical patent/NO20066070L/no
Publication of NO342135B1 publication Critical patent/NO342135B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives en farmasøytisk blanding som omfatter en bærer og et virkestoff, hvor bæreren er minst én fiskegelatin forutbestemt på grunnlag av molekylvektprofilen av gelatinen. I enkelte utførelsesformer, særlig når konsentrasjonen av bærer utgjør en relativt lav andel av totalblandingen, kan bæreren være utelukkende en høymolekylær fiskegelatin, eller utgjøres av en blanding med gelatin av standard molekylvekt, hvor en høymolekylær gelatin utgjør en fremherskende del. I de utførelsesformer hvor konsentrasjonen av bærer utgjør en relativt større andel av totalblandingen, kan bæreren utelukkende være en fiskegelatin med standard molekylvekt, eller utgjøres av en blanding hvor nevnte gelatin med standard molekylvekt utgjør en fremherskende del. Blandinger kan således fremstilles for å optimalisere ytelsen av forskjellige gelatinkonsentrasjonsformuleringer som trengs.
NO20066070A 2004-06-03 2006-12-29 Fremgangsmåte for formulering av hurtig-dispergerende former omfattende fiskegelatin og fast, oral, raskt disintegrerende doseform av en farmasøytisk aktiv substans NO342135B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/860,106 US7972621B2 (en) 2004-06-03 2004-06-03 Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
PCT/US2005/019589 WO2005120464A1 (en) 2004-06-03 2005-06-03 Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight

Publications (2)

Publication Number Publication Date
NO20066070L true NO20066070L (no) 2007-02-27
NO342135B1 NO342135B1 (no) 2018-03-26

Family

ID=35449231

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20066070A NO342135B1 (no) 2004-06-03 2006-12-29 Fremgangsmåte for formulering av hurtig-dispergerende former omfattende fiskegelatin og fast, oral, raskt disintegrerende doseform av en farmasøytisk aktiv substans

Country Status (19)

Country Link
US (1) US7972621B2 (no)
EP (1) EP1765299B1 (no)
JP (1) JP5144258B2 (no)
KR (1) KR101161430B1 (no)
CN (2) CN102172345B (no)
AU (1) AU2005251773B2 (no)
BR (1) BRPI0511067B8 (no)
CA (1) CA2567830C (no)
DK (1) DK1765299T3 (no)
ES (1) ES2654293T3 (no)
HU (1) HU230429B1 (no)
IL (1) IL179777A (no)
IS (1) IS8588A (no)
MX (1) MXPA06013921A (no)
NO (1) NO342135B1 (no)
PL (2) PL218958B1 (no)
RU (1) RU2415665C2 (no)
WO (1) WO2005120464A1 (no)
ZA (1) ZA200610664B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
EP1898873A1 (en) * 2005-05-19 2008-03-19 Kilda Biolink AS Gelatin-containing topical composition
DE102006033168A1 (de) * 2006-07-10 2008-01-17 Gelita Ag Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung einer vernetzenden therapeutischen Zusammensetzung
CA2716901C (en) * 2008-02-28 2018-07-03 R.P. Scherer Technologies, Llc Process to minimize polymorphism
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
PT3095441T (pt) * 2010-10-08 2021-01-14 Scherer Technologies Llc R P Forma de dosagem de dissolução rápida de vacina oral utilizando amido
CA3045043A1 (en) 2016-12-31 2018-07-05 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
CN115154440A (zh) 2018-06-27 2022-10-11 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
JP2023543710A (ja) * 2020-09-17 2023-10-18 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 流動特性を改善するための、高分子量魚ゼラチンに基づく投薬製剤を伴う、界面活性剤の使用
WO2022074127A2 (en) * 2020-10-08 2022-04-14 Catalent U.K. Swindon Zydis Limited Stable oral dispersible formulation for epinephrine and salts or solvates thereof
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103634A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Improved use of cannabinoids in the treatment of epilepsy
KR20240075774A (ko) 2021-06-11 2024-05-29 오르파이 테라퓨틱스 인코포레이티드 안정화된 아필리모드 조성물 및 이의 용도
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
GB2111423B (en) 1981-12-02 1985-06-26 Wyeth John & Brother Ltd Making quick-dissolving pills
US4760093A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4760094A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4767789A (en) 1986-10-21 1988-08-30 American Home Products Corporation (Del.) Spray dried acetaminophen
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5215756A (en) 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
IL105553A (en) * 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage form comprising a porous network of matrix forming material which disperses rapidly in water
EP0622413B1 (en) 1992-11-11 2002-02-27 Toray Industries, Inc. Polyester films for magnetic recording media
US6726928B2 (en) 1994-10-28 2004-04-27 R.P. Scherer Technologies, Inc. Process for preparing solid dosage forms for unpalatable pharmaceuticals
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
ATE288255T1 (de) 1996-04-12 2005-02-15 Novadel Pharma Inc Polares bukkales spray
US6258380B1 (en) 1999-03-05 2001-07-10 Banner Pharmacaps, Inc. Chewable soft capsule
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) * 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6709699B2 (en) * 2000-09-27 2004-03-23 Kabushiki Kaisha Toshiba Film-forming method, film-forming apparatus and liquid film drying apparatus
US6706669B2 (en) * 2001-07-13 2004-03-16 Exxonmobil Research And Engineering Company Method for inhibiting corrosion using phosphorous acid
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
AU2003233118B8 (en) * 2002-05-07 2009-07-30 Ferring Bv Desmopressin in an orodispersible dosage form
GB2388776B (en) * 2002-05-21 2004-08-25 Croda Int Plc Succinylated fish gelatin for use as a blood plasma expander
GB0226076D0 (en) 2002-11-08 2002-12-18 Rp Scherer Technologies Inc Improved formulations containing substituted imidazole derivatives

Also Published As

Publication number Publication date
HUP0700043A3 (en) 2012-09-28
BRPI0511067B1 (pt) 2018-11-06
IL179777A0 (en) 2007-05-15
IS8588A (is) 2006-12-28
RU2006147244A (ru) 2008-07-20
HUP0700043A2 (en) 2009-03-02
EP1765299A1 (en) 2007-03-28
NO342135B1 (no) 2018-03-26
ZA200610664B (en) 2007-12-27
KR20070039524A (ko) 2007-04-12
KR101161430B1 (ko) 2012-07-02
RU2415665C2 (ru) 2011-04-10
CN102172345A (zh) 2011-09-07
PL1765299T3 (pl) 2018-05-30
US20050271719A1 (en) 2005-12-08
WO2005120464A1 (en) 2005-12-22
EP1765299B1 (en) 2017-11-15
ES2654293T3 (es) 2018-02-13
IL179777A (en) 2015-09-24
JP2008501709A (ja) 2008-01-24
JP5144258B2 (ja) 2013-02-13
CN102172345B (zh) 2018-05-04
HU230429B1 (hu) 2016-06-28
EP1765299A4 (en) 2011-03-09
DK1765299T3 (en) 2018-01-22
US7972621B2 (en) 2011-07-05
BRPI0511067A (pt) 2007-12-26
CA2567830C (en) 2013-08-13
BRPI0511067B8 (pt) 2021-05-25
AU2005251773A1 (en) 2005-12-22
CN1960710A (zh) 2007-05-09
AU2005251773B2 (en) 2010-12-16
PL382307A1 (pl) 2007-08-20
PL218958B1 (pl) 2015-02-27
MXPA06013921A (es) 2007-01-26
CA2567830A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
NO20066070L (no) Fremgangsmate for formulering av hurtig-dispergerende former omfattende minst et fiske gelatin valgt pa grunnlag av molekylvekt
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
WO2009072007A3 (en) Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
CR11167A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos
NO20071614L (no) Amitraz sammensetninger
BRPI0413927B8 (pt) composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
NO20090407L (no) Aerosolformulering for inhalering av beta agonister
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
NO20060631L (no) Fast dispersjon av takrolimus
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
DK1171101T3 (da) Fremgangsmåde til fremstilling af en vanduoplöselig amorf depotmatrix
EA200702593A1 (ru) Высококонцентрированные композиции, применимые для борьбы с экто- и эндопаразитами
EE05124B1 (et) Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine
WO2005065639A3 (en) Novel pharmaceutical compositions
BRPI0411759A (pt) uso do etanol como plastificante para preparar implantes subcutáneos contendo princìpios ativos termolábeis dispersos em uma matriz plga
SG155939A1 (en) Phosphoindoles as hiv inhibitors
PA8618401A1 (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol
BRPI0409330A (pt) eliminador de oxigênio ativo derivado de substáncia natural e seu uso
BRPI0516224A (pt) produto alimentìcio contendo um ou vários microorganismos vivos e pelo menos um ingrediente alimentìcio bioativo de interesse, processo de preparação do mesmo, e, utilização de um produto alimentìcio
HRP20020071B1 (hr) Farmaceutske kompozicije i pripravljanje istih
WO2020178805A3 (en) Preparation for topical use for dermatological treatments
WO2007060208A3 (en) Fast-dissolving isotropic expanded microporous composition or structure for pharmaceutical, veterinary, dietetic, food or cosmetic use and method for obtaining same

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CATALENT U.K. SWINDON ZYDIS LIMITED, GB